MARATTO

article · Egyptian Journal of Chemistry

New multi-functionalized pyridines: Facile synthesis, anti-cancer evaluation and in silico molecular docking

Abstract

Developing new compounds with bioactivity, especially against tumors, targeting G-quadruplexes is of great importance. In this direction, some new phthalimide-incorporating pyridine derivatives were synthesized using the phthalimido-acetophenone derivative 1 as a key precursor. Three-component cyclocondensation of compound 1 with various aryl aldehydes and ethyl cyanoacetate or malononitrile utilizing ammonium acetate as the nitrogen source afforded 4-substituted-6-(4-phthalimidophenyl)pyridin-2-one-3-carbonitriles (2a-e) or 2-amino-4-substituted-6-(4-phthalimidophenyl)pyridine-3-carbonitriles (3a,b), respectively. Characterization of these derivatives were identified on the basis of elemental analysis and spectroscopic tools such as nuclear magnetic resonance (NMR) and infrared (IR). Additionally, the potency of the targeted molecules as anticancer agents was assessed against two carcinogenic human cell lines, namely, colon cancer (HCT-116) and human prostate cancer (PC3) cells. The synthesized derivatives exhibited promising cytotoxicity in which compounds 2a and 2b have the strongest potency towards the two cancer cell lines comparable with doxorubicin (Dox). The conducted molecular docking studies revealed that the investigated compounds possess a good correlation between their anti-cancer activities and binding effectiveness with both c-MYC and KRAS G-quadruplexes.

Research topics

  • Synthesis and biological activity

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/ejchem.2024.311706.10306

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.